| Aggressive natural killer cell leukemia/lymphoma: case report, use of telesynergy and review of the literature. | |
| | |
MedLine Citation:
|
PMID: 15360011 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Natural killer cell malignancies, although increasingly recognized, remain rare tumors within the USA and Europe. They are somewhat more common in Asia, and have been best characterized within this population. We present a case of a young Caucasian woman who presented acutely with an aggressive natural killer cell leukemia/lymphoma. Use of Telesynergy technology enabled a transatlantic telemedicine conference with colleagues in a center of expertise. Unfortunately the patient was ultimately refractory to both conventional chemotherapy and Campath-1H and her disease course was fulminant, as has been described previously in this condition. We review the possible therapeutic options for this extremely aggressive malignancy and briefly discuss our center's experience of telemedicine technology. |
| | |
Authors:
|
Joanne Murdock; Elaine S Jaffe; Wyndham H Wilson; Damian T McManus; H Denis Alexander; T C M Curly Morris |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 45 ISSN: 1042-8194 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2004 Jun |
Date Detail:
|
Created Date: 2004-09-13 Completed Date: 2004-10-08 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: England |
Other Details:
|
Languages: eng Pagination: 1269-73 Citation Subset: IM |
Affiliation:
|
Haematology Department, Belfast City Hospital, Belfast, BT9 7AB, N. Ireland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / therapeutic use* Antibodies, Neoplasm / therapeutic use* Drug Resistance, Neoplasm Fatal Outcome Female Humans Killer Cells, Natural / immunology*, pathology* Leukemia / drug therapy, immunology, pathology* Lymphoma / drug therapy, immunology, pathology* Telemedicine* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Neoplasm; 0/alemtuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Richter's syndrome in the brain first manifested as an ischaemic stroke.
Next Document: Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab.